Immunization of rhesus macaques with Echinococcus multilocularis recombinant 14-3-3 antigen leads to specific antibody response

详细信息    查看全文

• 作者：Karen Lampe ; B. Gottstein ; T. Becker ; C. Stahl-Hennig ; F.-J. Kaup…
• 关键词：Echinococcus multilocularis ; Fox tapeworm ; Alveolar echinococcosis ; Non ; human primate ; Vaccination ; 14 ; 3 ; 3 protein
• 刊名：Parasitology Research
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：116
• 期：1
• 页码：435-439
• 全文大小：373KB
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Medical Microbiology; Microbiology; Immunology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-1955
• 卷排序：116

文摘

E. multilocularis (Em) is the etiologic agent of alveolar echinococcosis (AE), a severe and potentially fatal disease, primarily affecting the liver of and occurring in aberrant intermediate hosts, e.g., humans and non-human primates. Due to increasing numbers of spontaneous cases of AE in the Old World monkey colonies of the German Primate Center, the question arose as to whether vaccination of non-human primates may represent a useful prophylactic approach. In this pilot study, the recombinant antigen Em14-3-3, which has provided a 97 % protection against E. multilocularis challenge infection in rodent models, was used for the first time to immunize rhesus macaques. In order to increase immunogenicity, the antigen was formulated with different adjuvants including Quil A®, aluminum hydroxide (alum), and muramyl dipeptide (MDP). Also, different vaccination regimens were tested. All vaccinated animals developed antigen-specific antibodies. While Quil A® induced a local adverse reaction, alum proved to be the most potent adjuvant in terms of induced antibody levels, longevity as well as tolerability. In conclusion, our pilot study demonstrated that recombinant Em14-3-3 is safe and immunogenic in rhesus monkeys. As a next step, efficacy of the vaccination remains to be explored.